Fluicell AB — Investor Relations & Filings

Fluicell is a biotechnology company focused on high-precision tissue engineering and therapeutics. The company's core technology is the Nexocyte™ platform, which leverages proprietary single-cell bioprinting and open-volume microfluidics to create precisely engineered biological tissues. The primary applications are in regenerative medicine, with an initial goal of developing transplantable tissues to treat type 1 diabetes, and in advanced drug development, providing tissue models for toxicity screening. Fluicell also commercializes a portfolio of microfluidic-based research instruments, including the BioPen and Dynaflow Resolve systems, for single-cell analysis and manipulation.